UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August ~~July 30~~20, 2013

Vansen Pharma Inc. (Exact name of registrant as specified in its charter)

Nevada		001-33715		20-2881151
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

101 Convention Centre Drive, Suite 700, Las Vegas, NV		89109
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: 775-636-6986

~~Moliere~~Okana NoVentures, Inc. ~~222,~~(Former ~~Torre~~name deor ~~Oficinas~~former address, ~~Col.~~if ~~Los~~changed ~~Morales~~since ~~Polanco,~~last report.)

Delgacion Miguel Hidalgo, Mexico City, Mexico

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into Material Definitive Agreement

Item 5.03	Amendments to Articles of Incorporation or Bylaws

Item 8.01	Other Items

On ~~July~~August 307, 2013, weour ~~entered~~board ~~into~~of ~~and~~directors ~~closed~~approved an ~~asset purchase~~ agreement ~~between our company~~ and ~~Vansen~~plan ~~Pharma,~~of ~~Inc. Pursuant~~merger to ~~the~~merge ~~agreement~~with weour ~~have~~wholly-owned ~~agreed~~subsidiary toVansen ~~purchase~~Pharma ~~the right~~Inc., ~~title~~a ~~and~~Nevada ~~interest~~corporation, to ~~certain~~effect ~~Spectracef®~~a ~~and~~name ~~cefditoren~~change ~~pivoxil~~from ~~products~~Okana ~~in the United States~~Ventures, ~~along~~Inc. ~~with~~to ~~related~~Vansen ~~contracts,~~Pharma ~~records, inventories and product registrations~~Inc. Vansen ~~will~~Pharma ~~retain~~Inc. ~~their~~was ~~right,~~formed ~~title~~solely ~~and~~for ~~interest to~~ the ~~products~~change inof ~~Canada~~name.

AsArticles ~~consideration for the purchase, we will pay Vansen $900,000 in cash and issue shares~~ of ~~our~~Merger ~~common~~to ~~stock~~effect in the ~~amount~~merger ofand ~~50.085%~~change of ~~our~~name ~~current~~were ~~issued~~filed and ~~outstanding~~became ~~shares~~effective ofwith ~~common~~the ~~stock,~~Nevada ~~which~~Secretary ~~issuance consists~~ of ~~3,625,000~~State ~~shares~~on ofAugust ~~common~~20, ~~stock~~2013.

~~Vansen~~In ~~Pharma~~addition isto the name change, our board of directors approved a ~~sales~~12 ~~and~~new ~~marketing~~for ~~organization~~one ~~focused~~(1) onold ~~specialty~~forward ~~pharmaceutical~~split ~~products~~of our authorized and issued and outstanding shares of common. ~~With~~A ~~its~~Certificate ~~US-based~~of ~~sales~~Change ~~force~~for the ~~company~~stock ~~sells its~~split ~~anti-infective~~was ~~product~~filed ~~Spectracef(R)~~ and ~~its~~became effective with the Nevada Secretary of State on August 20, 2013. Consequently, our authorized ~~generic (cefditoren~~share ~~pivoxil)~~capital increased from 100,000,000 to ~~major~~1,200,000,000 ~~wholesalers~~shares of common stock and ~~pharmacy~~our ~~chains~~issued and outstanding common stock increased from7,066,667 to 84,800,004 shares, all with a par value of $0.001.

~~Vansen~~These ~~focuses~~amendments onhave ~~broad~~been ~~therapeutic~~reviewed ~~areas~~by ~~which~~the ~~are~~Financial ~~still~~Industry ~~anticipated~~Regulatory toAuthority ~~grow~~(FINRA) and ~~present~~have anbeen ~~opportunity~~approved for ~~major~~filing ~~expansion.~~with ~~Vansen~~an ~~will~~effective ~~grow~~date ~~its~~of ~~commercial~~August ~~presence by adding complimentary products through in–licensing~~30, ~~co-promotion and acquisitions; building a commercialized product portfolio~~2013.

InThe ~~regards~~forward tosplit ~~the~~and ~~assets~~name ~~that~~change wewill ~~have~~become ~~acquired~~effective ~~from~~with ~~Vansen,~~the ~~SPECTRACEF® and~~Over-the-Counter ~~its~~Bulletin ~~authorized~~Board ~~generic~~at ~~(cefditoren~~the ~~pivoxil) are effective~~opening ~~antibiotic~~of ~~therapy~~trading inon aAugust ~~patient-friendly~~30, ~~dose~~2013 ~~pack~~under ~~offering~~the ~~convenience~~symbol ~~and~~“OKNVD”. ~~promoting~~The ~~compliance. SPECTRACEF® (cefditoren~~"D" ~~pivoxil)~~will ~~tablets~~be ~~are~~placed ~~indicated~~on ~~for~~our ~~treatment~~ticker ofsymbol ~~mild~~for to20 ~~moderate~~business ~~infections in~~days. ~~patients~~Effective 12September ~~years~~30, of2013, ~~age~~our orticker ~~older~~symbol ~~caused~~will bychange ~~susceptible~~to ~~strains~~VNSN. ofOur ~~the~~new ~~following~~CUSIP ~~microorganisms:~~number is 92209Y101.

· Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae.

Item 9.01		Financial Statements and Exhibits
3.1		Articles of Merger filed with the Nevada Secretary of State on August 14, 2013 with an effective date of August 20, 2013.
3.2		Certificate of Change filed with the Nevada Secretary of State on August 14, 2013 with an effective date of August 20, 2013.

· Community-Acquired Pneumonia caused by Haemophilus influenzae.

· Pharyngitis/Tonsillitis caused by Streptococcus pyogenes.

· Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus.

Concurrently with the agreement with Vansen, we have also entered into a private placement subscription agreement with an investor pursuant to which we have received gross proceeds of US$1,450,000 for the issuance of 3,152,174 (post 12 for one forward split) shares of our common stock, at a price of $0.46 per share on a post split basis.

Item 3.02 Unregistered Sales of Equity Securities

Effective July 30, 2013, we issued 3,625,000 shares of common stock to Vansen, a non U.S. person (at that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933.

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Effective July 30, 2013, Maria Peralta resigned as a director and officer of our company and Richard Azani and Patrick Charles Frankham were appointed directors of our company. Also effective July 30, 2013, Richard Azani was appointed as our president, secretary, chief financial officer and treasurer.

Richard Azani

Since March 30, 2011, Mr. Azani has been a director of Neurokine Pharmaceuticals Inc. Mr. Azani has has been the president, chief executive officer, chief financial officer and director of A5 Laboratories, Inc. since March 2010.

He also has been the president and chief executive officer of Vida Nutra Pharma since 2003. From 1996 to 2006 Mr. Azani was the president and chief executive officer of Actilab Pharma Inc. and from 1994 to 1996, he was the vice-president of Analex Laboratory.

Mr. Azani received his B.Sc. in biochemistry and analytical chemistry and his M.Sc. in structural determination of protein using N.M.R. and X-ray at the University of Toulouse – France. Mr. Azani also received his Ph.D. at the University of Toulouse – France and his Post-Doctorate at McGill University – Montreal Canada.

Patrick Charles Frankham

Dr. Frankham has over 18 years of experience in the biopharmaceutical and services industries. Prior to joining Boehringer Ingelheim, he founded several multinational healthcare startup enterprises including healthcare information technology, services and pharmaceuticals companies. His professional experience includes public and private companies as well as multinational corporations. Notable prior organizations where he held increasing leadership roles include, Phoenix International Life Sciences (MDS Pharma Services), Endoceutics Inc., AeternaZentaris, BioAxone Biosciences, & ICON Clinical Research.

Our board of directors now consists of Richard Azani and Patrick Charles Frankham. There have been no transactions between our company and Richard Azani and Patrick Charles Frankham since our last fiscal year which would be required to be reported herein.

Item 8.01 Other Items

On July 30, 2013, our board of directors approved the change of our name to “Vansen Pharma Inc.”. We anticipate that the name change will be effected through an agreement and plan of merger to merge with and into our wholly-owned subsidiary, which shall be formed solely for the change of name.

In addition to the name change, our board of directors approved a forward split of our authorized and issued and outstanding shares of common stock on a one old for twelve (12) new basis, such that our authorized capital will be increased from 100,000,000 shares of common stock to 1,200,000,000 shares of common stock and, correspondingly, our issued and outstanding shares of common stock will be increased from 3,525,000 shares of common stock to 42,300,000 shares of common stock, all with a par value of $0.001, after taking into account the issuance to Vansen referred to herein.

These amendments will be submitted for review with the Financial Industry Regulatory Authority (“FINRA”). We will announce the completion of FINRA review and the effectiveness of these changes on the market by filing a Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

10.1 Asset purchase agreement between our company and Vansen Pharma, Inc., dated July 30, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OKANA VENTURES, INC.
Date: August 8, 2013	By:	/s/ Richard Azani
		Name: Richard Azani
		Title: President and Director

VANSEN PHARMA INC.

/s/ Richard Azani
Richard Azani
President and Director
Date: August 30, 2013

Filing Compare · Vansen Pharma Inc.